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Translational Relevance 37 
In order for cancer vaccination strategies to realise their potential, they must elicit 38 
effective anti-tumor immune responses in a broad patient population. Tumor cell 39 
purification dramatically improves RNA sequencing resolution to the point where 40 
novel, highly differentially expressed, immunogenic proteins become detectable. This 41 
novel methodology of tumor antigen identification could enhance future vaccine 42 
efficacy.  43 
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Abstract 44 
Purpose: Broadly expressed, highly differentiated tumor-associated antigens (TAA) 45 
can elicit anti-tumor immunity. However, vaccines targeting TAAs have 46 
demonstrated disappointing clinical results, reflecting poor antigen selection and/or 47 
immunosuppressive mechanisms.  48 
Experimental design: Here, a panel of widely expressed, novel colorectal TAAs 49 
were identified by performing RNA sequencing of highly purified colorectal tumor 50 
cells in comparison to patient-matched colonic epithelial cells; tumor cell purification 51 
was essential to reveal these genes. Candidate TAA protein expression was 52 
confirmed by immunohistochemistry, and pre-existing T cell immunogenicity towards 53 
these antigens tested.  54 
Results: The most promising candidate for further development is DNAJB7 [DnaJ 55 
heat shock protein family (Hsp40) member B7], identified here as a novel cancer-56 
testis antigen. It is expressed in many tumors and is strongly immunogenic in 57 
patients with cancers originating from a variety of sites. DNAJB7-specific T cells 58 
were capable of killing colorectal tumor lines in vitro, and the IFN-+ response was 59 
markedly magnified by control of immunosuppression with cyclophosphamide in 60 
cancer patients. 61 
Conclusion: This study highlights how prior methods that sequence whole tumor 62 
fractions (i.e. inclusive of alive/dead stromal cells) for antigen identification may have 63 
limitations. Through tumor cell purification and sequencing, novel candidate TAAs 64 
have been identified for future immunotherapeutic targeting.  65 
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Introduction 66 
Despite understandable excitement surrounding results from cancer immunotherapy 67 
studies, actual outcomes are disappointing. We recently demonstrated the principle 68 
that immunological responses generated to the 5T4 oncofetal antigen through MVA-69 
5T4 (TroVax) vaccination can positively influence the outcome of patients with 70 
advanced colorectal cancer (CRC)(1). Whilst survival was significantly prolonged for 71 
vaccinated patients mounting an anti-5T4 response, all patients had progressed 72 
within 10-months. Indeed, stand-alone anti-cancer vaccines are rarely effective in the 73 
advanced disease setting; this could be the result of inherent mechanisms of local 74 
immunosuppression, or sub-optimal antigenic targets. 75 
 Many upregulated tumor-associated antigen (TAA) targets are often readily 76 
detectable in healthy tissue, e.g. the autoantigen carcinoembryonic antigen (CEA)- 77 
and directing immune responses against such antigens can lead to side-effects (2) 78 
and poor survival outcomes post-surgery (3). Thus, identification of TAAs that can be 79 
targeted by immunotherapy is a balance between expression on tumor and healthy 80 
tissue. The challenge is further complicated by T cell cross-reactivity which can 81 
result in off-target effects in distant tissue with potentially fatal consequences (4). 82 
Whilst immunotherapies targeting neoepitopes hold promise, they are highly 83 
focused to the individual and currently prohibitively expensive to develop. For 84 
therapies relevant to the wider population such as cancer vaccines, antigens must 85 
be broadly expressed in the same tumor types of multiple individuals and present at 86 
minimal levels in healthy tissue. Ideal discovery pipelines would involve large scale 87 
analysis of TAA candidates followed by selection based on immunogenicity and 88 
tissue-specific expression. Candidates that fit these criteria could be explored further 89 
with cancer vaccination and CAR-T cell therapy. Indeed, vaccinations targeting non-90 
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mutated tumor antigens are capable of inducing robust T cell responses in cancer 91 
patients (1,5).  92 
The development of RNA-sequencing in differential expression analysis 93 
provides an attractive methodology to initiate TAA discovery pipelines. However, this 94 
technology is limited by the heterogeneity of the tissue in question and is not 95 
extensively used in TAA discovery. For the colon, a mixture of immune cells, 96 
epithelium and stroma complicates expression profiles, limiting identification of 97 
significantly differential expressed genes especially when tumor immune infiltrate 98 
varies highly between individuals and tumor location. Purification of epithelial and 99 
tumor cells prior to RNA-sequencing analysis is a novel methodology developed to 100 
overcome tissue heterogeneity. In this study, we used EpCAM purification of tumor 101 
and healthy colonic epithelium at two sites to improve the resolution between 102 
expression profiles and thus aid identification of differentially expressed genes 103 
(DEG). Gene lists were created based on expression profiles between all tissues, 104 
and significance levels in a DESeq2 comparison analysis. These lists were analysed, 105 
and several genes selected for further investigation. Immunogenic analysis and 106 
tissue expression of the protein products of these genes in healthy tissues were 107 
used to select the best candidate for cancer immunotherapy. 108 
  109 
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Materials and Methods 110 
Excision of colonic and tumor tissue 111 
Tumor and paired background (unaffected) colon specimens were obtained from 112 
three patients undergoing anterior resection for primary rectal cancer at the 113 
University Hospital of Wales, Cardiff (see Supplementary Table 1 for patient 114 
characteristics). Autologous colon samples were cut from macroscopically normal 115 
sections of the excised tissue, both “near” (within 2 cm) and “far” (at least 10 cm) 116 
from the tumor site. All fresh tumor samples were derived from the luminal aspect of 117 
the specimen, so as not to interfere with histopathological staging. All patients and 118 
participants gave written, informed consent personally prior to inclusion. This study 119 
was conducted in accordance with the Declaration of Helsinki. The Wales Research 120 
Ethics Committee granted ethical approval for this study. 121 
Patient treatment schedule 122 
Orally administered 50mg cyclophosphamide was taken twice-a-day on treatment 123 
days 1–7 and 15–21; no cyclophosphamide was taken on treatment days 8–14 or 124 
22–106, or until patient relapsed. Peripheral blood samples (40ml) were taken at 125 
regular intervals during therapy.  126 
Purification of tissue samples 127 
Background colon and tumor specimens were transported and washed in extraction 128 
medium supplemented with 2% human AB serum (Welsh Blood Service), gentamicin 129 
and Fungizone (ThermoFisher). Within 30-minutes of resection from a patient, 130 
samples were minced and forced through 70m cell strainers to collect a single cell 131 
suspension. In no instances were collagenase or DNase treatments used. 132 
Dissociated cell preparations of tumor, near and far healthy colonic tissue were 133 
stained with Live/Dead fixable Aqua (ThermoFisher) followed by surface marker 134 
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staining with CD3-APC (BioLegend) and EpCAM-PE (Miltenyi Biotec) antibodies. 135 
Samples were resuspended in FACS buffer (PBS, 2% BSA) prior to sorting into 136 
Live/Dead-EpCAM+CD3- populations on a FACS Aria III (BD). Tumor tissue also 137 
stained with CD3 and EpCAM antibodies was additionally passed through the cell 138 
sorter without gating, and used as an unsorted control for RNA-sequencing. All 139 
samples were sorted directly into RLT buffer (Qiagen) with -mercaptoethanol 140 
(Sigma Aldrich) and frozen at -80˚C. Frozen samples were thawed and RNA isolated 141 
using an RNeasy Micro kit (Qiagen). 142 
RNA sequencing 143 
Library preparation and RNA sequencing was carried out by VGTI-FL (Florida, USA). 144 
Purified RNA was used to make libraries using an Illumina TruSeq kit. Libraries were 145 
sequenced to a depth of 37-63 M read pairs on an Illumina HiSeq platform. Paired 146 
end reads were processed on a Cardiff University pipeline. Reads were trimmed with 147 
Trimmomatic (28) and assessed for quality using FastQC 148 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) using the default 149 
parameters. Reads were mapped to Ensembl human genome build GRCh38.89 150 
downloaded from the Ensembl FTP site 151 
(http://www.ensembl.org/info/data/ftp/index.html/) using STAR (29). Counts were 152 
assigned to transcripts using featureCounts with the GRCh38.89 gene build GTF 153 
(30). RNA-seq data have been deposited in the ArrayExpress database at EMBL-154 
EBI (www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-8803. 155 
Differential expression analysis 156 
Aligned reads were normalised using DESeq2 in R (31). Differentially expressed 157 
genes were identified between purified tumor samples, purified near, and purified far 158 
epithelium. Differential expression analysis was carried out using DESeq2 between 159 
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sample types for all donors in a paired analysis. Comparisons of tumor and near or 160 
far normal epithelial tissue were carried out. For the three-donor expression analysis, 161 
genes with a Log 2-fold change greater than 3.5, FPKM values in healthy tissue less 162 
than 3.5, and FPKM values in tumor greater than 4.0 in any two of three donors and 163 
p-adjusted < 0.05 (Benjamini and Hochberg (8), in three donors) were taken forward 164 
for further analysis. 165 
The analysis was expanded to genes which were significantly differentially 166 
expressed in separate comparisons for data in two of the three donors. Higher 167 
expression cut off values were used with FPKM greater than 5.0 in both donor’s 168 
tumor tissue, and less than 1.0 in healthy tissues, with a log 2-fold change greater 169 
than 6 and p-adjusted < 0.05.  170 
Analysis of TCGA RNA-seq data 171 
Level 3 (raw counts, htseq.counts.gz) RNA-seq data, and sample meta data (GDC 172 
sample sheet and clinical cart files) were downloaded from the TCGA GDC portal 173 
(https://portal.gdc.cancer.gov/) on 15-May-2018 for colon and rectal adenocarcinoma 174 
patients (TCGA-COAD, TCGA-READ). All datasets were normalized as one matrix 175 
using DESeq2 in R and output normalized counts were used for all analyses, with 176 
data visualized using the pheatmap R package. 177 
Antigens 178 
20mer peptides overlapping by 10 amino acids, covering the entire protein sequence 179 
of each identified TAA, were synthesized by Fmoc chemistry to >95% purity (GL 180 
Biochem), and divided into pools, as shown (Supplementary Tables 2-8). Individual 181 
9mer peptides (to measure HLA-A*02-restricted DNAJB7-specific CD8+ T cell 182 
responses) were synthesised by Fmoc chemistry to >90% purity (Peptide 183 
Synthetics). The recall antigens tuberculin purified protein derivative (PPD; Statens 184 
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Serum Institut) and hemagglutinin (HA; gift from Dr. John Skehel, National Institute 185 
of Medical Research) and the T cell mitogen phytohemagglutinin (PHA; Sigma) were 186 
used as positive controls. All antigens were used at a final concentration of 5g/ml.  187 
Peripheral blood mononuclear cell (PBMC) culture 188 
Peripheral blood samples were obtained from pre-operative colorectal 189 
adenocarcinoma patients (n=17), hepatocellular carcinoma patients (n=2), 190 
cholangiocarcinoma patient (n=1), head and neck carcinoma patients (n=2) and age-191 
matched non-tumor-bearing donors (n=10). Blood samples were collected in 10ml 192 
heparin tubes (BD) no more than 7-days prior to surgery. PBMCs were isolated by 193 
centrifugation of heparinized blood over Lymphoprep (Axis-Shield). Cells were 194 
washed and re-suspended in CTL Test Plus media (CTL Europe), L-glutamine and 195 
penicillin / streptomycin. PBMC were plated in 96-well plates (Nunc) and cultured in 196 
duplicate wells with specific antigens for 14-days, supplemented with fresh media 197 
containing 20 IU/ml IL-2 on days 3, 7 and 10.  198 
Generation of DNAJB7 9mer epitope-specific CD8+ T cell lines  199 
PBMCs from two healthy donors and one CRC patient, who were known HLA-A*02 200 
positive, were used to generate CD8+ T cell lines. The HLA class I epitope prediction 201 
algorithms NetMHC 4.0 (32) and SYFPEITHI (33) were used to identify HLA-A*02-202 
restricted DNAJB7 9mers predicted to bind with the highest affinity. PBMCs were 203 
stimulated with the top five scoring DNAJB7-derived 9mer epitopes in the presence 204 
of 40 IU/ml IL-2, 2 ng/ml IL-7, and 5 ng/ml IL-15, in CTL Test Plus culture media. 205 
Cells were incubated in 37°C, 5% CO2 for 9-12 days before testing their specificity 206 
by IFN- ELISPOT or intracellular cytokine staining. CD8+ T cells from positive lines 207 
were sorted by MojoSort CD8 T cell isolation kits (Biolegend, UK), and further 208 
expanded using irradiated T2 cells, loaded with relevant peptides, and irradiated 209 
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autologous PBMCs as feeders. Cells were rested for a minimum of three days in 210 
media containing no cytokines before use in downstream assays. 211 
Adenovirus vectors and cell lines 212 
The replication deficient (E1/E3) adenovirus vectors Ad5-DNAJB7 (expressing the 213 
entire DNAJB7 ORF (open reading frame)) and Ad5-EMPTY (lacking an inserted 214 
ORF) were generated in the AdZ vector system, using homologous recombineering 215 
methods as previously described (34,35). The DNAJB7 ORF was gene synthesized 216 
by GeneArt (ThermoFisher Scientific, UK), prior to being inserted into the AdZ 217 
vector. Viruses were produced in T-REx-293 and purified as previously described 218 
(36). 219 
 The colorectal tumor cell lines SW480 (European Collection of Authenticated 220 
Cell Cultures (ECACC) 87092801) and Caco-2 (ECACC 86010202) were used in 221 
this study, given their confirmed expression of HLA-A*02 and the coxsackie and 222 
adenovirus receptor (data not shown). Cell lines were transduced using 2500 virus 223 
particles (vp) per cell (SW480) or 10,000 vp/cell (Caco-2) of Ad5 vector expressing 224 
DNAJB7 under the control of a CMV promoter, or control empty Ad5 vector for 3 225 
hours at 37°C 5% CO2 in media containing FBS. After the incubation period, cells 226 
were washed with fresh media and cultivated according to culture collection 227 
protocols (ECACC), before use in downstream assays.  Ad5-GFP titration and 228 
subsequent flow cytometric analyses had been performed prior to Ad5-DNAJB7 229 
transduction to determine the optimal vp/cell dose for each cell line. Vp/ml of each 230 
adenovirus was quantified using a Pierce Micro BCA Protein Assay Kit. 231 
Western blot 232 
Protein was extracted from SW480 and Caco-2 cells using 4x NUPAGE LDS sample 233 
buffer (ThermoFisher Scientific). Protein (6-9g) was resolved using 4-12% sodium 234 
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dodecyl sulphate polyacrylamide electrophoresis gels at 120V for 90 minutes and 235 
transferred to PVDF membrane at 30V for 80 minutes at room temperature. 236 
Membranes were blocked using 5% milk in PBS plus 0.05% Tween 20 (PBST) and 237 
incubated with DNAJB7 antibody (1:1000, rabbit IgG, polyclonal, Bio-Techne) or β-238 
actin antibody (1:2000, rabbit IgG, monoclonal, Sigma-Aldrich) overnight at 4°C. 239 
Antibodies were prepared in 0.05% milk in PBST. Secondary antibody (1:3000, Anti-240 
rabbit IgG, Bio-Rad) was applied for 1-hour at room temperature. Images of the 241 
bands were visualized using SuperSignal Pico PLUS chemiluminescent substrate 242 
(ThermoFisher Scientific). 243 
Real-time cytotoxicity assay (xCelligence) 244 
Target SW480 or Caco-2 cells were harvested and plated at 20,000 and 12,000 cells 245 
per well, respectively, in a 96-well xCelligence E-plate (ACEA Biosciences). 246 
Transduction was performed 48 hours prior to plating where appropriate. Suitable 247 
cell densities were determined by previous titration experiments. Cell attachment 248 
was monitored using the xCelligence Real-Time Cell Analysis (RTCA) instrument 249 
until the plateau phase was reached. DNAJB7-specific CD8+ T cell lines were added 250 
at an effector to target ratio of 5:1 and impedance measurements performed every 251 
10 minutes for up to 72 hours. All experiments were performed in duplicate. Changes 252 
in electrical impedance were expressed as a dimensionless cell index value, 253 
normalized to impedance values immediately preceding the addition of effector T 254 
cells. 255 
ELISpot / FluoroSpot Assays 256 
IFN- ELISpot and IFN-/Granzyme B FluoroSpot assays were performed as 257 
previously described (13). Briefly, PVDF 96-well filtration plates were coated with 258 
50l antibody (Mabtech). Cells were washed, plated, and stimulated with 5g/ml 259 
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antigen in duplicate wells. Plates were incubated at 37oC, 5% CO2 for 24-hours 260 
before developing spots. Spot-forming cells (SFC), i.e. cytokine-producing T cells, 261 
were enumerated using SmartCount settings on an automated plate reader 262 
(ImmunoSpot S6 Ultra; CTL Europe). Positive responses were identified as having at 263 
least 20 SFC/105 cultured PBMCs, and at least double that of the negative (no 264 
antigen) control. Wells with spot counts >1000 were deemed too numerous to count 265 
and capped at this level. 266 
Flow cytometry 267 
To perform T cell counts, 15μl of human TBNK 6-colour cocktail (BioLegend) was 268 
added to 50μl of whole heparinized blood using a reverse pipetting technique. Red 269 
blood cells were lyzed and samples run on a NovoCyte 3000 (ACEA Biosciences) to 270 
obtain absolute cell counts. To calculate the proportion of proliferating CD4+ 271 
regulatory T cells, fresh PBMCs were stained with Live/Dead-Aqua (ThermoFisher 272 
Scientific), surface stained with CD3-FITC, CD4-BV605 and CD25-BV421 273 
(BioLegend), followed by fixation / permeabilization and intracellular staining with 274 
Foxp3-APC (ThermoFisher Scientific) and Ki67-PE (BD Biosciences).  275 
Immunohistochemistry 276 
The identified TAAs from this study were evaluated for protein expression 277 
characteristics on healthy tissue and a range of tumor samples by utilising the 278 
Human Protein Atlas resource (12). In addition, DNAJB7 expression was assessed 279 
on formalin-fixed paraffin embedded blocks of colorectal tumor and healthy colon 280 
tissue (see Supplementary Table 1 for patient characteristics), and testis tissue as a 281 
positive control for DNAJB7 expression. Immunohistochemistry was performed on 282 
the Leica Bond RX Automated Research Stainer. Dewaxing/hydration of 5m 283 
sections was performed according to manufacturer’s instructions (Leica). Antigen 284 
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retrieval was performed using Bond Epitope Retrieval Solution 2. DNAJB7 antibody 285 
(HPA000534, Atlas Antibodies) was used at a dilution of 1:100 and incubated for 105 286 
minutes. Antibody detection was performed using Bond Polymer Refine Detection 287 
Kit, followed by hematoxylin counter staining. Following this, samples were 288 
dehydrated, mounted then scanned using Slide Scanner Axio Scan.Z1 (Zeiss); 289 
representative images were taken using Zen Blue software.  290 
  291 
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Results 292 
Purification of samples prior to RNA-sequencing provided enhanced 293 
resolution of differentially expressed genes  294 
Rectal tumor and paired background (unaffected) colon specimens were 295 
obtained from three patients undergoing resection. Autologous colon samples were 296 
cut from macroscopically normal sections of the excised tissue, both “near” (within 2 297 
cm) and “far” (at least 10 cm) from the tumor site (Figure 1A). Dissociated single 298 
cells were sorted into Live/Dead-EpCAM+CD3- populations (Figure 1B and C). 299 
EpCAM was chosen as it would enable preferential isolation of epithelial populations 300 
over stromal tissue and immune populations (6,7).  301 
RNA-sequencing datasets were comparable following several normalization 302 
procedures. Differential expression comparisons were run using DESeq2 of healthy 303 
tissues (“near” and “far”) against purified tumor tissue in all three patients, and then 304 
separate analyses for each combination of two patients. An additional comparison of 305 
non-purified tumor tissue against healthy tissues was run to investigate the impact of 306 
EpCAM sorting. To find relevant genes that could be targeted by immunotherapy, we 307 
applied criteria that specified very low levels of expression in healthy tissue 308 
combined with high expression in tumor tissue (based on FPKM and log 2-fold 309 
change). Only genes assigned a p-adjusted < 0.05 (Benjamini and Hochberg (8)) 310 
were taken forward for further analysis. 311 
Initial gene lists gave 83 significant genes showing differential expression 312 
between tumor and far colon tissue, while 92 genes between tumor and near colon 313 
tissue. Cross referencing of these gene lists resulted in five genes that satisfied 314 
significant criteria in both comparisons (including four of those taken forward; ARSJ, 315 
CENPQ, ZC3H12B and CEACAM3). To expand our analysis, we looked at DEGs 316 
which were significantly expressed in tumor tissue of two of three patients to a higher 317 
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level (increased expression cut-offs and lower threshold of healthy tissue 318 
expression). These gene lists were combined with three donor lists, and then near 319 
and far tissue cross referenced (Figure 2A). This gave an initial set of 54 genes 320 
which were cut to 23 based on levels of expression in healthy tissue of all three 321 
donors (Supplementary Figure 1 and Supplementary Table 9). Of these 23 genes, 322 
18 were protein coding. We inspected these 18 genes and selected those which 323 
were most suitable for further analysis, eliminating those involved in the central 324 
nervous system, or which exhibited an inconsistent expression or read mapping 325 
profile in three donors gauged by visual curation of mapped reads in IGV (Integrative 326 
Genomics Viewer, Broad Institute) (9). 327 
The final genes selected were DNAJB7, CENPQ, ZC3H12B, ZSWIM1, 328 
CEACAM3, ARSJ and CYP2B6, based on their ideal expression profile for 329 
therapeutic exploitation (Figure 2B). Inspection of expression profiles in non-purified 330 
tumor tissue (Figure 2B and 2D) exemplified the difficulty in detecting these genes in 331 
the absence of purification, with all expression levels lower than purified tissue. 332 
To further assess the impact of tissue purification, we looked at the DEGs between 333 
bulk and EpCAM sorted tumor samples, focusing on genes which were expressed in 334 
at least two of the three samples (Figure 2C). This emphasised the advantage of 335 
purification resulting in enhancement of the most relevant gene expression patterns 336 
and demonstrates how our novel antigens could not have been identified from bulk 337 
tumor sequencing alone (Figure 2D). 338 
Comparison of Common Cancer Antigen Expression 339 
 We next wanted to assess the expression patterns of the seven novel 340 
antigens identified in the context of other antigens commonly classified in the 341 
literature as TAAs (10,11). We compiled a representative list which included antigens 342 
such as GP100, 5T4, LAGE3 and MART and looked at how their expression levels 343 
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compared within the patient samples used in this study (Figure 3A) and across both 344 
colon and rectal tumor data from the TCGA (Figure 3B). This analysis showed a 345 
clear distinction in antigen expression level, with CYP2B6, ZSWIM1 and 5T4 346 
expression comparable to the highly expressed LAGE3. However, beyond these four 347 
genes the expression levels of other antigens were heterogeneous across tumor 348 
samples, and some appeared to be relatively low in the TCGA data, in particular 349 
CEACAM3 and DNAJB7. 350 
 A critical criterion for the analysis in Figure 2 was differential expression of 351 
genes between healthy tissue and tumor tissue. The TCGA data also has several 352 
paired datasets of colon and rectal tumors and corresponding heathy tissue. We 353 
visually inspected the differences of the TAA panel list across these datasets in order 354 
to confirm that our antigen still accorded with this criterion in a large publicly 355 
available dataset (Figure 3C). Indeed, when healthy and tumor tissue expression of 356 
each were compared, the differentially expressed nature of several antigens was 357 
emphasised. For DNAJB7, ZSWIM1 and CENPQ, the contrast between healthy and 358 
tumor datasets was skewed towards tumor expression and suggested these would 359 
be better targets than ARSJ or CYP2B6 which did not show visual distinction 360 
between the two tissue types. Furthermore, other cancer antigens could be classified 361 
as having highly favorable (WT1, LAGE3, MART1, AFP) or hypothetically dangerous 362 
(ACRBP, SPA17, KLK3) expression patterns between healthy and tumor tissues, 363 
and as such their assessment as bona fide TAAs should be reconsidered. Such 364 
trends were also present in our data (Figure 3D). 365 
Analysis of protein expression across multiple healthy tissues highlights 366 
DNAJB7 as a cancer-testis antigen and a suitable target for immunotherapy 367 
The protein expression level of each candidate TAA was evaluated using 368 
publicly available immunohistochemistry data (12). Whilst each candidate exhibited 369 
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significant upregulation on tumor tissue over healthy tissue (with the possible 370 
exception of ARSJ), DNAJB7, a protein belonging to the evolutionarily conserved 371 
DNAJ heat shock family, was unexpectedly identified as a novel cancer-testis 372 
antigen given its complete lack of expression on any healthy tissue bar the testis, an 373 
immune-privileged site (Supplementary Figure 2).  374 
We sought to corroborate this pattern of staining on paraffin-fixed samples 375 
acquired in-house, using the same anti-DNAJB7 antibody (HPA000534). In 376 
preliminary experiments, expression was higher in certain tumor samples, although 377 
antibody staining was observed in background colon tissue (Supplementary Figure 378 
3). Given this finding and the failure to detect DNAJB7 mRNA in normal colon, we 379 
conclude that where DNAJB7 is detected, it is preferentially expressed in cancer 380 
tissue. 381 
Furthermore, DNAJB7 was expressed on a very wide range of solid tumors, in 382 
particular on tumors of the gastrointestinal tract and accessory organs of digestion, 383 
including colorectal cancer and pancreatic ductal adenocarcinoma (Supplementary 384 
Figures 2B and 2C).  385 
DNAJB7 is a superior cancer-testis antigen 386 
 The expression profile of DNAJB7 was compared to six other well-defined 387 
cancer-testis antigens, including NY-ESO-1, MAGE-A1 and SSX2. High protein 388 
expression of all these antigens was confirmed to be confined to the testis 389 
(Supplementary Figure 4A). In comparison to the other cancer-testis antigens, 390 
DNAJB7 was expressed on the greatest range of tumor types, with more than 67% 391 
of all patients tested exhibiting positive (low, medium or high) protein expression on 392 
their tumor, except for lymphoma (Supplementary Figure 4B).  393 
Analysis of candidate TAA TH1 responses reveal DNAJB7 to be immunogenic  394 
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Following identification of relevant genes and confirmed protein expression, 395 
we assessed their immunogenicity using overlapping peptide pools and culture with 396 
PBMC of CRC patients and healthy donors. Analysis of cultured PBMC by IFN-γ 397 
ELISpot determined three of the seven proteins to demonstrate immunogenicity in 398 
most donors tested (Figure 4A-B). As the size of peptide libraries was highly variable 399 
for each protein, we standardized the immunogenicity relevant to the number of 400 
peptides in each pool (Figure 4A). This analysis revealed CYP2B6, DNAJB7 and 401 
CEACAM3 to be comparably immunogenic across multiple individuals without 402 
stratification by HLA-type, and similarly immunogenic to the oncofetal antigen 5T4, a 403 
tumor antigen that has successfully been targeted in CRC previously (1,13). 404 
Conversely, CENPQ and ARSJ were poorly immunogenic in most donors tested. 405 
Furthermore, our peptide pool design allowed us to interrogate 406 
immunogenicity based on a matrix format to determine the peptides responsible for 407 
the positive T cell responses (example for DNAJB7, Supplementary Figure 5). This 408 
type of analysis may be important for isolation of TH1 stimulating regions of TAA 409 
which can be incorporated in vaccines based on immunogenic components of 410 
multiple antigens important in CRC, as well as being regions that can be targeted by 411 
epitope-based modifications and strategies for enhancement of the immune 412 
response (14). An example of one CRC patient revealed positive IFN- and 413 
granzyme B responses to DNAJB7 peptide pools 3, 6 and 10, indicative of T cell 414 
responses to epitopes contained within peptides 3 and 23 (Supplementary Figure 5B 415 
and C). Indeed, peptide 23 was the most immunogenic region of the DNAJB7 416 
protein, with responses discovered in 39% of CRC patient and healthy control 417 
donors tested (Supplementary Figure 5D). DNAJB7 was also found to be 418 
immunogenic in patients with other tumor types, including hepatocellular carcinoma, 419 
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cholangiocarcinoma and the non-gastrointestinal head and neck squamous cell 420 
cancer (Figure 4C). 421 
CD8+ T cell recognition of DNAJB7-expressing colorectal tumor cell lines 422 
 TH1 responses described above were dominated by IFN--secreting CD4
+ 423 
effector T cells, favoured by the longer 20mer peptides used to stimulate the 424 
PBMCs. However, analysis of specific IFN- and granzyme B production using 425 
FluoroSpot assays indicates that granzyme B is abundantly produced in response to 426 
the DNAJB7 peptides (9/10 donors tested, Figure 5A and Supplementary Figure 5) 427 
suggesting cytotoxic T cell responses are present. In order to ascertain whether 428 
these responses were indicative of CD8+ T cells capable of killing DNAJB7-429 
expressing tumor cells, HLA-A*02-restricted CD8+ T cell epitopes derived from 430 
DNAJB7 were identified by computer-based epitope prediction algorithms (Figure 431 
5B). The top five scoring peptides stimulated cognate CD8+ T cells derived from 432 
HLA-A*02+ healthy donors and a CRC patient. DNAJB7-specific CD8+ T cell lines 433 
were successfully enriched in all donors, an example of responses to peptides 434 
LTFFLVNSV and GMDNYISVT is shown (Figure 5C). 435 
 The HLA-A*02-expressing SW480 and Caco-2 colorectal tumor cell lines were 436 
used as targets in a cytotoxicity assay, however there was minimal expression of 437 
DNAJB7 in both lines (Figure 5D and Supplementary Figure 6). Cell lines were 438 
successfully transduced with an Ad5-DNAJB7 viral vector and found to stably 439 
increase DNAJB7 expression over a 5-day period before reducing on day 6 (Figure 440 
5D and Supplementary Figure 6). Upon addition of effector DNAJB7-specific CD8+ T 441 
cells to target colorectal tumor cells, real-time impedance traces show a highly 442 
significant (P<0.0001) reduction in the number, size/shape, and/or attachment 443 
quality of DNAJB7-expressing Caco-2 cells (Figure 5E), and a reduction in the 444 
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growth of DNAJB7-expressing SW480 cells (Figure 5F) over Ad5-EMPTY 445 
transduced or non-transduced, untreated (UT) tumor cell lines. Non-specific 446 
(DNAJB7-negative) T cell lines did not cause additional killing to DNAJB7-expressing 447 
targets, compared to Ad5-EMPTY or UT cell lines (data not shown). Hence, 448 
DNAJB7-expressing tumor cell lines present peptides on the cell surface by MHC 449 
class I and are selectively eliminated by DNAJB7-specific CD8+ T cells. 450 
Anti-DNAJB7 TH1 responses are induced during cyclophosphamide treatment 451 
We have previously demonstrated that anti-tumor TH1 effector responses are 452 
controlled by regulatory T cells (Tregs) (15), and that targeting these Tregs either by 453 
depletion in vitro, or inhibition/depletion in vivo with low dose cyclophosphamide, 454 
increases the anti-tumor (5T4) immune response (1,13). We sought to assess 455 
whether T cell responses were induced to the novel tumor antigens in a CRC patient 456 
(Figure 6) and an HCC patient (Supplementary Figure 7) receiving short-term 457 
metronomic cyclophosphamide. Anti-5T4 TH1 responses increased by >4-fold in both 458 
patients, an effect previously identified as associating with improved survival 459 
outcomes (13); intriguingly, anti-DNAJB7 TH1 responses also mirrored this treatment 460 
response profile in both instances, whereas no responses were induced to ARSJ, 461 
CENPQ, ZSWIM1 and CYP2B6 (Figure 6B and C, and Supplementary Figure 7A 462 
and B). This could suggest that responses to DNAJB7 and CEACAM3 are 463 
suppressed in CRC and HCC, given that responses were unmasked by efficient 464 




The pursuit of new cancer vaccines that can be administered regardless of patient 468 
HLA-type or neoantigen load relies on the investigation and discovery of novel TAAs. 469 
Paired RNA-sequencing of tumor and healthy tissue facilitates TAA identification but 470 
is limited by the diversity of cellular input in each sequencing sample. Here we 471 
purified EpCAM+ cellular populations from healthy colon and primary colorectal 472 
tumors; RNA-sequencing data from purified samples revealed multiple genes that 473 
showed significant differential expression across three donors.  474 
In a comparison with non-purified tumor tissue, no genes were classified as 475 
significant according to the same criteria, demonstrating the power of using purified 476 
tissues in antigen discovery. Further analyses of differentially expressed gene lists in 477 
tissues near and far from the tumor helped identify 18 genes which showed 478 
differential expression patterns suitable for therapeutics. Four protein products of the 479 
identified genes exhibited significant immunogenicity in healthy donors and cancer 480 
patients; of these DNAJB7 also demonstrated the most favorable expression profile 481 
based on immunohistochemistry data of healthy and cancerous tissue. DNAJB7 482 
belongs to the evolutionarily conserved DNAJ/Heat Shock Protein (HSP)40 family of 483 
proteins and is a molecular chaperone to HSP40. It is likely that its upregulation in 484 
tumors is in response to increased expression of many heat shock proteins, aiding 485 
tumor cell proliferation in hostile environments (16). Indeed, other HSP40 family 486 
members DNAJB6 and DNAJB8 have both been previously shown to be upregulated 487 
in cancer, contributing to cancer-initiating cell maintenance (17-19). Therapies 488 
targeting heat shock proteins and their molecular chaperones are already showing 489 
promise in cancer treatment (20). Immunotherapeutic targeting of these proteins may 490 
also yield further anti-cancer benefits, as implicated by this study. 491 
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Robust TH1 responses to DNAJB7 and several other novel tumor antigens 492 
were found in healthy controls, in keeping with previous findings for tumor-493 
associated antigens from our laboratory (21,22) and others (23,24). It is possible 494 
these responses are indicative of a normal functioning process of 495 
immunosurveillance to remove aberrant epithelial cells. The presence or absence of 496 
such responses are now beginning to be exploited for cancer diagnostics and 497 
prognostication ((24) and NCT02840058). How and why these T cells exist and are 498 
maintained at such a frequency in the memory pool remains unknown: possibilities 499 
range from transient upregulation of TAAs during periods of inflammation, e.g. of the 500 
colon (22), incomplete thymic selection or antigenic cross-reactivity / mimicry to 501 
microbial proteins (25).  502 
 There are limitations to our study, including the selection of luminal tumor 503 
sites for cell enrichment as opposed to the invasive margin (required for 504 
histopathological assessment of the tumor), the use of purification procedures, i.e. 505 
fluorescence activated cell sorting, that may influence mRNA expression prior to 506 
RNA isolation, and low initial sample size. However, despite the relatively small 507 
scale, the approach described here has successfully identified novel, highly antigenic 508 
proteins expressed in cancers. These antigens could be incorporated into vaccines 509 
for both therapeutic and prophylactic use. One goal of cancer vaccination in the 510 
context of CRC immunotherapy is to reduce relapse rates following surgical 511 
intervention. Curative rates following resection of primary colorectal tumors are ~60-512 
70% but could be improved if relapse was prevented by safely boosting immunity to 513 
the proteins with differential expression patterns as a form of prophylactic 514 
immunotherapy (26). Indeed, loss of anti-tumor immune responses associates with 515 
advancing tumor stage (21,22), and these patients can benefit from anti-cancer 516 
vaccination strategies. At the moment, although there is some success using a 517 
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single TAA in CRC (1), better therapeutic strategies are necessary with superior 518 
vaccine targets combined with manipulations of immune regulation. These 519 
approaches necessitate discovery of more TAAs and greater investigation of the 520 
negative impacts of T cell cross-reactivity and off-target immune effects. Questions 521 
over the ideal differential expression pattern, specifically the extent to which some 522 
expression in healthy tissue can be tolerated relative to tumor expression are highly 523 
relevant. In addition, the targeting of multiple tumor antigens is more likely to 524 
overcome inherent tumor immune evasion and evolution. However, cancer-testis 525 
antigens allay some of these concerns and represent an ideal tumor target for 526 
immunotherapy (27). Indeed, here we identified that most donors have the capability 527 
to mount anti-DNAJB7 T cell responses, and these responses can be significantly 528 
boosted in cancer patients receiving cyclophosphamide. Enhancing this anti-tumor 529 
immune response could hold significant potential in future therapeutic and 530 
prophylactic treatment strategies. 531 
  532 
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Figure Legends  678 
Figure 1. Isolation of epithelial and tumor cells by EpCAM-sorting prior to RNA-679 
seq. (A) Schematic of tumor and healthy tissue resection taken at two distances from 680 
the tumor site. Samples were taken from rectal tumor of three patients. (B) Sample 681 
processing and purification flow chart. (C) Flow cytometry gating for EpCAM+ and CD3- 682 
purification, pre and post cell sorting.  683 
Figure 2. Identification of candidates for further investigation based on differential 684 
expression analysis. (A) Workflow for obtaining gene lists of differentially expressed 685 
genes based on two comparisons (purified tumor versus purified healthy colon “far,” and 686 
purified tumor versus purified healthy colon “near,” left-hand side and right-hand side, 687 
respectively). Gene lists were obtained from significantly differentially expressed genes 688 
across all three patients and separately in two of three patients. These were aligned and 689 
cross referenced between “far” and “near” comparisons to give a smaller gene list which 690 
was further reduced based on expression in healthy tissue, and finally suitability for 691 
further investigation. (B) Normalized counts for each of the seven genes selected for 692 
further analysis. Counts are shown for each of the four conditions as box plots 693 
representing all three patients. (C) Heatmap showing 317 genes that were differentially 694 
expressed between EpCAM purified and bulk tumor samples and were expressed in at 695 
least two of three EpCAM purified samples. Normalized counts were scaled by gene to 696 
show relative expression between each sample. (D) Heatmap of novel tumor antigen 697 
gene expression (in addition to 5T4), showing differences in normalized counts between 698 
EpCAM purified and bulk tumor, scaled as part (C). 699 
Figure 3. (A) Heatmap showing relative expression levels of known and novel TAAs 700 
using normalized counts scaled by sample across EpCAM purified tumor. (B) 701 
Corresponding analysis using TCGA data for rectal (green bar) and colon (purple bar) 702 
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tumors scaled by sample. (C) Comparison of expression levels between tumor and solid 703 
tissue normal in available TCGA data, scaled by gene. Sample type and tissue/tumor 704 
location (colon or rectal) are indicated in the top two bars. (D) Corresponding analysis 705 
performed on our EpCAM purified tumor and healthy data. 706 
Figure 4. Immunogenicity of candidate TAAs. T cell responses to peptide pools 707 
spanning the entire protein sequence of each candidate TAA were assessed by cultured 708 
IFN- ELISpot (see Supplementary Tables 2-8 for peptide sequences). The total number 709 
of IFN-+ spot-forming cells (SFC) per 105 cultured PBMC relative to the number of 710 
peptides spanning the protein was assessed and ranked by mean response (grey bars) 711 
amongst all donors tested (A) and then subdivided by CRC patients (blue circles TNM 712 
Stage 1/2; n=6, black circles TNM Stage 3; n=8) and healthy donors (‘HD’, white circles; 713 
n=10) (B). (C) Patients with other gastrointestinal cancers were tested for their ability to 714 
mount anti-DNAJB7 T cell responses (CC – cholangiocarcinoma; HCC – hepatocellular 715 
carcinoma; HNC – head and neck squamous cell carcinoma).  716 
Figure 5. Enriched DNAJB7-specific CD8+ T cells target DNAJB7-expressing 717 
colorectal tumor cell lines. T cell responses to two peptide pools spanning the entire 718 
DNAJB7 protein sequence were assessed by cultured Granzyme B FluoroSpot (see 719 
Supplementary Table 2 for peptide sequences). The total number of Granzyme B+ spot-720 
forming cells (SFC) per 105 cultured PBMC relative to the 30 peptides spanning the 721 
DNAJB7 protein was assessed in 9 CRC patients (A). (B) HLA class I epitope prediction 722 
algorithms were used to identify HLA-A*02-restricted DNAJB7 9mers predicted to bind 723 
with the highest affinity; top 5 across the algorithms are indicated. (C) DNAJB7-specific 724 
CD8+ T cells were enriched in multiple donors, a representative example of the IFN- 725 
response in one T cell line to DNAJB7 epitopes LTFFLVNSV and GMDNYISVT is 726 
shown. (D) The SW480 CRC cell line was transduced with Ad5-DNAJB7 or an Ad5-727 
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EMPTY vector, with the expression of DNAJB7 protein indicated by the band at 35kDa 728 
and actin control at 45kDa. UT = untreated (non-transduced) SW480 cells. DNAJB7-729 
specific T cell lines from a healthy donor (‘Donor 1’) and a CRC patient (‘Donor 2’) were 730 
seeded into 96-well E-plates, co-incubated with the indicated transduced / non-731 
transduced Caco-2 (E) or SW480 (F) cell lines at an effector to target ratio of 5:1. 732 
Changes in impedance over a 24-hour period, normalized at the timepoint immediately 733 
preceding the addition of effector T cells, are given as a dimensionless normalized cell 734 
index. Experiments were performed in duplicates. Statistical results of two-way ANOVA 735 
are indicated (*** P<0.0001).  736 
Figure 6. Regulatory T cell depletion unmasks TH1 responses to novel TAAs. (A) A 737 
post-colectomy CRC patient received low-dose, metronomic cyclophosphamide on 738 
treatment days 1-8 and 15-22, with blood samples collected weekly throughout 739 
treatment. T cell responses to peptide pools spanning the entire protein sequence of 740 
each candidate TAA were assessed by cultured IFN- ELISpot at each timepoint; 741 
example images of IFN- ELISpot wells are shown (B). (C) The total number of IFN-+ 742 
spot-forming cells (SFC) per 105 cultured PBMC (mean of duplicate wells) were 743 
calculated for each TAA. (D) CD3+CD4+CD25hiFoxp3+ regulatory T cell numbers and 744 
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